|Videos|March 15, 2022
Decentralized Clinical Trials in a Covid-19 Landscape
Author(s)YPrime
YPrime President, Mark Maietta, discusses the future of decentralized clinical trials following Covid-19. Adaptations will need to be made as DCT is here to stay.
• Regulatory has begun to investigate new methods and technologies for the clinical trial process.
• Clinical trials will have more decentralized components going forward.
• The key is matching a protocol and patient with the new components of DCT.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Content
Trending on Applied Clinical Trials Online
1
How the FDA’s CNPV Program Is Reshaping Trial Operations and Accelerated Review Strategies
2
Former FDA Commissioners Warn New Vaccine Policies Could Undermine Longstanding Regulatory Framework
3
Voyxact Lands FDA Accelerated Approval Following Positive Results in Phase III VISIONARY Trial
4
Drug Repurposing Through AI-Driven In-Silico Clinical Trials
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
